Unlike Alzheimer’s disease (AD), where imaging markers for tracing amyloid-β up to 25 years prior to clinical symptom onset are available, to date, no synuclein tracer has been validated, thus other imaging modalities are used in PD. This evidence concerns the gene SNCA and Alzheimer disease.